282 related articles for article (PubMed ID: 15219819)
1. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
Muccioli GG; Wouters J; Charlier C; Scriba GK; Pizza T; Di Pace P; De Martino P; Poppitz W; Poupaert JH; Lambert DM
J Med Chem; 2006 Feb; 49(3):872-82. PubMed ID: 16451053
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1).
Hillard CJ; Manna S; Greenberg MJ; DiCamelli R; Ross RA; Stevenson LA; Murphy V; Pertwee RG; Campbell WB
J Pharmacol Exp Ther; 1999 Jun; 289(3):1427-33. PubMed ID: 10336536
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors.
Govaerts SJ; Hermans E; Lambert DM
Eur J Pharm Sci; 2004 Nov; 23(3):233-43. PubMed ID: 15489124
[TBL] [Abstract][Full Text] [Related]
6. Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation.
Muccioli GG; Martin D; Scriba GK; Poppitz W; Poupaert JH; Wouters J; Lambert DM
J Med Chem; 2005 Apr; 48(7):2509-17. PubMed ID: 15801840
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
[TBL] [Abstract][Full Text] [Related]
8. 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists.
Muccioli GG; Wouters J; Scriba GK; Poppitz W; Poupaert JH; Lambert DM
J Med Chem; 2005 Nov; 48(23):7486-90. PubMed ID: 16279809
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
10. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
Siehler S; Nunn C; Zupanc GK; Hoyer D
Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
Behrenswerth A; Volz N; Toräng J; Hinz S; Bräse S; Müller CE
Bioorg Med Chem; 2009 Apr; 17(7):2842-51. PubMed ID: 19278853
[TBL] [Abstract][Full Text] [Related]
12. Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387.
McLaughlin PJ; Qian L; Wood JT; Wisniecki A; Winston KM; Swezey LA; Ishiwari K; Betz AJ; Pandarinathan L; Xu W; Makriyannis A; Salamone JD
Pharmacol Biochem Behav; 2006 Mar; 83(3):396-402. PubMed ID: 16616951
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
[TBL] [Abstract][Full Text] [Related]
15. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1.
Mo FM; Offertáler L; Kunos G
Eur J Pharmacol; 2004 Apr; 489(1-2):21-7. PubMed ID: 15063151
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
17. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.
Felder CC; Joyce KE; Briley EM; Glass M; Mackie KP; Fahey KJ; Cullinan GJ; Hunden DC; Johnson DW; Chaney MO; Koppel GA; Brownstein M
J Pharmacol Exp Ther; 1998 Jan; 284(1):291-7. PubMed ID: 9435190
[TBL] [Abstract][Full Text] [Related]
18. The effects of charge-neutralizing mutation D6.30N on the functions of CB1 and CB2 cannabinoid receptors.
Nebane NM; Kellie B; Song ZH
FEBS Lett; 2006 Oct; 580(22):5392-8. PubMed ID: 16989818
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
20. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.
Marini P; Cascio MG; King A; Pertwee RG; Ross RA
Br J Pharmacol; 2013 Jun; 169(4):887-99. PubMed ID: 23711022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]